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Contrib. No.
Given name(s) Surname Suffix Despite the unprecedented success of tyrosine kinase inhibitors (TKIs), the clinical management of 20 -30% of patients with chronic myeloid leukemia (CML) experiencing primary or secondary resistance to imatinib mesylate (IM) continues to be challenging [1 -3] . Early identifi cation of these patients would indicate a more potent agent upfront, or alternative drug following the initial suboptimum response, or stem cell transplant (SCT) prior to the subject becoming refractory to further treatment. Th erefore, a biomarker with proven clinical utility of predicting patients ' response to IM would assist considerably in optimizing clinical management for such patients. Recently, investigators reported that Src homology 2 domain-containing phosphatase-1 ( SHP-1 ) expression levels at diagnosis were prognostic and predictive of TKI response in patients with CML [4] . Previously, others suggested that down-regulation of SHP-1 contributes to constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling and disrupts protein phosphatase 2A (PP2A) mediated BCR -ABL11 elimination, thereby triggering CML transformation [5] . Th erefore, we retrospectively studied 97 cDNA samples from patients with highly heterogeneous CML to assess the clinical utility of measuring SHP-1 mRNA levels in patients with CML (Table I) . Th e samples were collected at various time points, refl ected by the overlap in BCR -ABL1 transcript numbers for those who achieved a major molecular response (MMR) and those who did not (Table I) . Of the 97 patients, 24 were had advanced disease (AD), i.e. accelerated phase (AP) n ϭ 6 and blast crisis (BC) n ϭ 18, and 73 patients were in highly heterogeneous chronic phase (CP) treated with diff erent modalities. For 35 of the 73 patients in CP the MMR status was available for assessing the clinical utility of SHP-1 levels. Among the 24 patients in AD, at least fi ve archived serial mRNA samples were available for each of the fi ve patients for longitudinal studies. Of these fi ve patients, four had been treated with one or more TKIs and one had undergone allogeneic SCT. We also included a cohort control of 77 diagnostic samples from a group of patients with heterogeneous acute myeloid leukemia (AML) and 18 normal control samples from adult volunteer blood donors, whose characteristics are detailed in Table I .
SHP-1 , BCR -ABL1 and endogenous control gene, GUS b , transcripts were quantifi ed by real time polymerase chain reaction (Q-PCR) as previously reported [6] . Standard curves were constructed for each assay using serial log dilutions of plasmid, ranging from 1 ϫ 10 3 to 1 ϫ 10 6 , with target gene specifi c insert. BCR -ABL1 and GUS b target sequences were included in one plasmid and the other included the SHP-1 insert (a kind gift from Professor F. Pane, Naples, Italy). Only those samples with Ն 5500 GUS b transcripts were evaluated for this report. Non-parametric Mann -Whitney tests were performed using PRISM software.
Briefl y, 38 of the 73 patients in CP were prescribed single agents: (interferon and cytarabine [ n ϭ 1]), IM ( n ϭ 30), nilotinib ( n ϭ 6) or dasatinib ( n ϭ 1). Th e remainder were treated with two or more agents, as were the 24 patients with AD. SHP-1 mRNA was detectable in all samples screened by Q-PCR (Table I) . However, a signifi cant diff erential in mRNA expression ( p Ͻ 0.0001) was observed between patients in CP and the normal control group. Furthermore, the SHP-1 transcripts were signifi cantly lower ( p ϭ 0.0001) in patients with AD, with a median of 14.0 (range 0.8 -211.9), in comparison to patients in CP, median 35.7 (range 5.2 -675.1). Similarly, we observed a signifi cant diff erence between patients with CML with AD and normal control samples ( p Ͻ 0.0001). However, we observed no signifi cant diff erence in SHP-1 levels between AML and normal control samples ( p ϭ 0.801). Th is is probably explained by the molecular heterogeneity among the patients with AML, in contrast to the single genetic lesion associated with CML, and that SHP-1 is reported to bind to BCR -ABL1.
In contrast to published data [4] we found no significant diff erence ( p ϭ 0.0966) between patients who failed to achieve a MMR within 18 months ( n ϭ 22) and those 2 J. Kaeda et al. patients who did ( n ϭ 13). To exclude the possibility that the statistical value might have been infl uenced by either the highly variable collection time-points or the diverse therapeutic agents administered, a restricted analysis of 15 patients treated with IM alone and for whom we had samples collected at diagnosis was performed. Even within this group we found no signifi cant diff erence ( p ϭ 0.4527), i.e. between those who did ( n ϭ 6) and failed to ( n ϭ 9) achieve MMR within 12 months. Th is did not change even when the criterion was extended to 18 months. Th is variance from published data may refl ect diff erences in the timing of sample collection during the course of treatment in this study and that reported by Esposito et al . [4] . However, these data do not exclude the possibility that assessing SHP-1 activity at the protein level would be predictive. Nevertheless, protein analysis is too complex for a clinical laboratory to perform, in contrast to Q-PCR analysis, and therefore not within the scope of this assessment.
In addition we noted no signifi cant diff erence in SHP-1 mRNA levels between those patients in CP who had been prescribed one ( n ϭ 37), two ( n ϭ 7) or Ն 3 TKIs ( n ϭ 8), which generally correlated with optimal, suboptimal and/or failed response.
Th e kinetics data were consistent with overall CP and AD results, showing that SHP-1 levels decreased as the BCR -ABL1 transcript numbers increased, i.e. an inverse relationship (Figure 1) , implying that regulatory control of the two is directly or indirectly linked. We did note that for patient 4, including the period when the subject was in CP (Figure 1 ), this relationship was not observed. However, there was no diff erence of note in this patient ' s clinical history compared to the other four subjects. More importantly, BCR -ABL1 transcripts in these fi ve patients were not preceded by a decrease in SHP-1 .
Given the relatively low levels of SHP-1 in comparison to BCR -ABL1 expression, we confi rmed that our assay could Figure 1 . SHP-1 and BCR -ABL1 kinetics. Kinetics data for SHP-1 (dashed lines) and BCR -ABL1 (solid lines) are shown for fi ve patients with CML included in the longitudinal study. Y -axis for SHP-1 levels is on the right of each graph. SHP-1 mRNA was detected in all samples tested for the fi ve patients and refl ected the BCR -ABL1 kinetics. SHP-1 levels did not predict a change in patients ' disease status, such that an increase or decrease in its expression did not precede a change in BCR -ABL1 transcript levels. Th erefore, we conclude that its predictive value is not superior to that of the disease specifi c marker, BCR -ABL1 .
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reproducibly detect a fi ve-fold change in SHP-1 mRNA levels by titrating, in duplicate, the SU-DHL-1 cell line with the LAMA-87 hematopoietic cell line. Th is is consistent with the generally accepted view that Q-PCR assays have a dynamic range of 5-log, although up to an 8-log range is achievable. Th erefore, the kinetics and MMR data suggest that measuring the SHP-1 mRNA level does not provide additional information for identifying patients at risk of disease progression or predicting response to TKIs beyond that gleaned from close regular monitoring by measurement of diseasespecifi c BCR -ABL1 transcripts. However, the diff erential expression of SHP-1 between CP and AD observed in this study was consistent with earlier reports suggesting that phosphatase antagonizes BCR -ABL1 ability to block differentiation [7, 8] . Reduced expression of SHP-1 might free BCR -ABL1 to recruit and activate JAK2. Active JAK2 has been reported to enhance β -catenin activity and inactivate PP2A mediated degradation of BCR -ABL1 , thus triggering BC [9] .
In conclusion, our data imply that SHP-1 levels fail to predict TKI response. However, in keeping with previous reports, our data provide further evidence to support the notion that SHP-1 plays a role in CML disease progression.
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